---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-058688"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:51:49.939995+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Roivant reports positive Phase 2 batoclimab data in Graves' disease; response >50%

## Summary
- Initial cohort in Phase 2 trial of batoclimab in Graves' disease showed response rates meaningfully exceeding 50%.
- Batoclimab 680 mg SC achieved up to 87% IgG reduction, mean 81% at 12 weeks; 340 mg showed lower reductions.
- Across clinical parameters, numerically higher responses with 680 mg vs 340 mg, including ATD dose reduction and discontinuation.
- Batoclimab generally well tolerated with no new safety signals observed in the initial data set.
- Immunovant plans to focus future Graves' development on IMVT-1402, with details expected later in 2024.

## SEC filing metadata
- accession: 0001140361-23-058688
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123058688/0001140361-23-058688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123058688/ef20017126_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-058688
- JSON: https://secwatch.observer/filing/0001140361-23-058688.json
- Plain text: https://secwatch.observer/filing/0001140361-23-058688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.